Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies
- PMID: 1731105
- PMCID: PMC240842
- DOI: 10.1128/JVI.66.2.1277-1281.1992
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies
Abstract
It was previously demonstrated that the vaccinia virus recombinants expressing the respiratory syncytial virus (RSV) F, G, or M2 (also designated as 22K) protein (Vac-F, Vac-G, or Vac-M2, respectively) induced almost complete resistance to RSV challenge in BALB/c mice. In the present study, we sought to identify the humoral and/or cellular mediators of this resistance. Mice were immunized by infection with a single recombinant vaccinia virus and were subsequently given a monoclonal antibody directed against CD4+ or CD8+ T cells or gamma interferon (IFN-gamma) to cause depletion of effector T cells or IFN-gamma, respectively, at the time of RSV challenge (10 days after immunization). Mice immunized with Vac-F or Vac-G were completely or almost completely resistant to RSV challenge after depletion of both CD4+ and CD8+ T cells prior to challenge, indicating that these cells were not required at the time of virus challenge for expression of resistance to RSV infection induced by the recombinants. In contrast, the high level of protection of mice immunized with Vac-M2 was completely abrogated by depletion of CD8+ T cells, whereas depletion of CD4+ T cells or IFN-gamma resulted in intermediate levels of resistance. These results demonstrate that antibodies are sufficient to mediate the resistance to RSV induced by the F and G proteins, whereas the resistance induced by the M2 protein is mediated primarily by CD8+ T cells, with CD4+ T cells and IFN-gamma also contributing to resistance.
Similar articles
-
The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.J Virol. 1993 Feb;67(2):1044-9. doi: 10.1128/JVI.67.2.1044-1049.1993. J Virol. 1993. PMID: 8419638 Free PMC article.
-
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.J Virol. 1991 Mar;65(3):1634-7. doi: 10.1128/JVI.65.3.1634-1637.1991. J Virol. 1991. PMID: 1995956 Free PMC article.
-
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3. Vaccine. 1992. PMID: 1609551
-
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.J Virol. 1995 Feb;69(2):1261-4. doi: 10.1128/JVI.69.2.1261-1264.1995. J Virol. 1995. PMID: 7815502 Free PMC article.
-
Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens.Vaccine. 2009 Dec 30;27 Suppl 6(Suppl 6):G21-6. doi: 10.1016/j.vaccine.2009.10.011. Vaccine. 2009. PMID: 20006135 Free PMC article. Review.
Cited by
-
The genetic effect of engineered vaccine on Pseudomonas aeruginosa infection in mice.Immunogenetics. 1993;38(4):280-2. doi: 10.1007/BF00188804. Immunogenetics. 1993. PMID: 8319977 No abstract available.
-
Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.J Virol. 1998 Nov;72(11):8971-5. doi: 10.1128/JVI.72.11.8971-8975.1998. J Virol. 1998. PMID: 9765442 Free PMC article.
-
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.J Virol. 2002 Feb;76(3):1089-99. doi: 10.1128/jvi.76.3.1089-1099.2002. J Virol. 2002. PMID: 11773385 Free PMC article.
-
Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology.Vaccine. 2008 Sep 2;26(37):4840-8. doi: 10.1016/j.vaccine.2008.06.100. Epub 2008 Jul 21. Vaccine. 2008. PMID: 18644416 Free PMC article.
-
Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.Clin Microbiol Rev. 1999 Apr;12(2):298-309. doi: 10.1128/CMR.12.2.298. Clin Microbiol Rev. 1999. PMID: 10194461 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials